Literature DB >> 12383771

The role of fibroblast growth factors in vascular development.

Sophie Javerzat1, Patrick Auguste, Andreas Bikfalvi.   

Abstract

Fibroblast growth factors (FGFs) are considered angiogenic factors, yet the exact relationship between FGF and vascular development in normal and pathological tissue has long remained elusive. However, recent results from gene inactivation and transgenic studies in mice and in culture systems have demonstrated the role of FGFs in vessel assembly and sprouting. FGFs also promote blood-vessel branching and induce lymphangiogenesis. Novel players in FGF-mediated angiogenesis have been identified, such as p38 mitogen-activated protein kinase. Tumour angiogenesis is regulated by FGFs directly or indirectly via secondary angiogenesis factors, such as vascular endothelial growth factor. The newly established angiogenic role of FGFs makes FGF or molecules targeting FGF and its receptor promising candidates for the development of novel therapeutics.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12383771     DOI: 10.1016/s1471-4914(02)02394-8

Source DB:  PubMed          Journal:  Trends Mol Med        ISSN: 1471-4914            Impact factor:   11.951


  70 in total

Review 1.  Beyond VEGF: inhibition of the fibroblast growth factor pathway and antiangiogenesis.

Authors:  Christopher Lieu; John Heymach; Michael Overman; Hai Tran; Scott Kopetz
Journal:  Clin Cancer Res       Date:  2011-09-27       Impact factor: 12.531

Review 2.  Antiangiogenic therapy in human gastrointestinal malignancies.

Authors:  J Heidemann; D G Binion; W Domschke; T Kucharzik
Journal:  Gut       Date:  2006-10       Impact factor: 23.059

3.  Glucocorticoid and growth factor synergism requirement for Notch4 chromatin domain activation.

Authors:  Jing Wu; Emery H Bresnick
Journal:  Mol Cell Biol       Date:  2007-01-12       Impact factor: 4.272

4.  Mesothelium of the murine allantois exhibits distinct regional properties.

Authors:  Jacob M Daane; Allen C Enders; Karen M Downs
Journal:  J Morphol       Date:  2011-01-31       Impact factor: 1.804

5.  A novel 2-aminobenzimidazole-based compound Jzu 17 exhibits anti-angiogenesis effects by targeting VEGFR-2 signalling.

Authors:  Jin-Cherng Lien; Chi-Li Chung; Tur-Fu Huang; Tsung-Chia Chang; Kuan-Chung Chen; Ging-Yan Gao; Ming-Jen Hsu; Shiu-Wen Huang
Journal:  Br J Pharmacol       Date:  2019-09-15       Impact factor: 8.739

Review 6.  Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.

Authors:  Yujie Zhao; Alex A Adjei
Journal:  Oncologist       Date:  2015-05-22

7.  Prox1 promotes lineage-specific expression of fibroblast growth factor (FGF) receptor-3 in lymphatic endothelium: a role for FGF signaling in lymphangiogenesis.

Authors:  Jay W Shin; Michael Min; Fréderic Larrieu-Lahargue; Xavier Canron; Rainer Kunstfeld; Lynh Nguyen; Janet E Henderson; Andreas Bikfalvi; Michael Detmar; Young-Kwon Hong
Journal:  Mol Biol Cell       Date:  2005-11-16       Impact factor: 4.138

Review 8.  Controlled protein delivery in the generation of microvascular networks.

Authors:  Jillian W Andrejecsk; William G Chang; Jordan S Pober; W Mark Saltzman
Journal:  Drug Deliv Transl Res       Date:  2015-04       Impact factor: 4.617

9.  A proangiogenic signature is revealed in FGF-mediated bevacizumab-resistant head and neck squamous cell carcinoma.

Authors:  Rekha Gyanchandani; Marcus V Ortega Alves; Jeffrey N Myers; Seungwon Kim
Journal:  Mol Cancer Res       Date:  2013-10-03       Impact factor: 5.852

10.  Bovine lactoferricin inhibits basic fibroblast growth factor- and vascular endothelial growth factor165-induced angiogenesis by competing for heparin-like binding sites on endothelial cells.

Authors:  Jamie S Mader; Daniel Smyth; Jean Marshall; David W Hoskin
Journal:  Am J Pathol       Date:  2006-11       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.